Although the complexity of cancer is well‐acknowledged, the implementation of precision cancer medicine until now has relied on discrete sets of isolated biomarkers (e.g. HR, HER2 and BRCA1/2 in breast cancer) [2]. This evidence concerns the gene ERBB2 and cancer.